Cellzome, Pfizer Partner on Epigenetics of Stem Cell Differentiation | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German chemoproteomics firm Cellzome today announced a collaboration with Pfizer to study epigenetic mechanisms involved in stem cell differentiation.

Cellzome will use its Episphere platform to characterize epigenetic changes while Pfizer's Pain & Sensory Disorders and Regenerative Medicine unit, Neusentis, will provide expertise in stem-cell handling and regenerative medicine.

Financial and other terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.